HPLC-MS/MS Shows That the Cellular Uptake of All--Retinoic Acid under Hypoxia Is Downregulated by the Novel Active Agent 5-Methoxyleoligin.

All--retinoic acid (aRA) is the essential derivative of vitamin A and is of interest due to its various biological key functions. As shown in the recent literature, aRA also plays a role in the failing heart during myocardial infarction, the leading cause of death globally. To date insufficient mechanistic information has been available on related hypoxia-induced cell damage and reperfusion injuries. However, it has been demonstrated that a reduction in cellular aRA uptake abrogates hypoxia-mediated cell and tissue damage, which may offer a new route for intervention. Consequently, in this study, the effect of the novel cardio-protective compound 5-methoxyleoligin (5ML) on cellular aRA uptake was tested in human umbilical-vein endothelial cells (HUVECs). For this purpose, a high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method was developed to assess intra-cellular levels of the active substance and corresponding levels of vitamin A and its derivatives, including potential / isomers. This work also focused on light-induced isomerization and the stability of biological sample material to ensure sample integrity and avoid biased conclusions. This study provides evidence of the inhibitory effect of 5ML on cellular aRA uptake, a promising step toward a novel therapy for myocardial infarction.